We are live on ! Find out more
OMED

OncoMed Pharmaceuticals, Inc.
OMED

Delisted

OMED was delisted on the 22nd of April, 2019.

Back to rankings

62 hedge funds and large institutions have $143M invested in OncoMed Pharmaceuticals, Inc. in 2014 Q3 according to their latest regulatory filings, with 6 funds opening new positions, 26 increasing their positions, 21 reducing their positions, and 7 closing their positions.

New
Increased
Maintained
Reduced
Closed

523% more call options, than puts

Call options by funds: $1.84M | Put options by funds: $295K

24% more repeat investments, than reductions

Existing positions increased: 26 | Existing positions reduced: 21

0% more funds holding in top 10

Funds holding in top 10: 1 → 1 (0)

2% less funds holding

Funds holding: 63 → 62 (-1)

8% less capital invested

Capital invested by funds: $155M → $143M (-$12.3M)

14% less first-time investments, than exits

New positions opened: 6 | Existing positions closed: 7

Holders
62
Holders Change
-1
Holders Change %
-1.59%
% of All Funds
1.8%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.03%
New
6
Increased
26
Reduced
21
Closed
7
Calls
$1.84M
Puts
$295K
Net Calls
+$1.54M
Net Calls Change
+$1.54M

Top Buyers

Rank Fund Capital Flow
1
BI
BVF Inc
California
+$9.29M
2
SAM
Sectoral Asset Management
Quebec, Canada
+$6.07M
3
CIP
Convergence Investment Partners
Florida
+$1.67M
4
T. Rowe Price Associates
T. Rowe Price Associates
Maryland
+$1.52M
5
Northern Trust
Northern Trust
Illinois
+$1.41M

Top Sellers

Rank Fund Capital Flow
1
CCI
Columbus Circle Investors
-$5.9M
2
Primecap Management
Primecap Management
California
-$965K
3
BIT
BlackRock Institutional Trust
California
-$948K
4
Invesco
Invesco
Georgia
-$892K
5
Renaissance Technologies
Renaissance Technologies
New York
-$384K
Name Holding Trade Value Shares
Change 		Change in
Stake
JP Morgan Chase
26
JP Morgan Chase
New York
$829K +$423K +21,071 +93%
TAM
27
Tocqueville Asset Management
New York
$802K -$16.1K -800 -2%
Renaissance Technologies
28
Renaissance Technologies
New York
$759K -$384K -19,090 -32%
BIM
29
BlackRock Investment Management
Delaware
$700K +$17.2K +855 +2%
SO
30
STRS Ohio
Ohio
$593K +$550K +27,347 +684%
Charles Schwab
31
Charles Schwab
California
$545K +$121K +6,012 +26%
GT
32
Glenmede Trust
Pennsylvania
$543K – – –
California State Teachers Retirement System (CalSTRS)
33
California State Teachers Retirement System (CalSTRS)
California
$440K +$2.65K +132 +0.6%
ProShare Advisors
34
ProShare Advisors
Maryland
$385K -$75.2K -3,741 -16%
TA
35
Teachers Advisors
New York
$333K – – –
HCM
36
Hodges Capital Management
Texas
$284K – – –
Millennium Management
37
Millennium Management
New York
$246K +$32.2K +1,601 +14%
CS
38
Credit Suisse
Switzerland
$244K -$269K -13,362 -51%
AL
39
Airain Ltd
Guernsey
$212K +$225K +11,208 New
Bank of Montreal
40
Bank of Montreal
Ontario, Canada
$208K -$42.6K -2,120 -16%
AIG
41
American International Group
New York
$207K -$2.91K -145 -1%
MLICM
42
Metropolitan Life Insurance Company (MetLife)
New York
$195K +$804 +40 +0.4%
NFA
43
Nationwide Fund Advisors
Ohio
$184K +$2.27K +113 +1%
Citigroup
44
Citigroup
New York
$176K +$5.1K +254 +3%
Swiss National Bank
45
Swiss National Bank
Switzerland
$142K – – –
AllianceBernstein
46
AllianceBernstein
Tennessee
$125K +$2.01K +100 +2%
BA
47
BlackRock Advisors
Delaware
$99K -$117K -5,842 -53%
BAM
48
Brave Asset Management
New Jersey
$99K +$106K +5,250 New
TC
49
Travelers Companies
Minnesota
$79K +$83.4K +4,152 New
U
50
UBS
Switzerland
$62K -$8.3K -413 -11%
1
2
3

OMED Hedge Fund Activity: Q3 2014 in Review

62 of the 3,447 institutional investors tracked by Wall St. Rank reported a position in OncoMed Pharmaceuticals, Inc. (OMED) for Q3 2014, worth a combined $143M — down 7.9% from $155M a quarter earlier.

Sellers outnumbered buyers: 7 funds closed out of OMED and 6 opened new positions — a net loss of 1 holder — while 21 trimmed existing stakes and 26 added.

The largest buyer was BVF Inc, adding an estimated $9.29M. The largest seller was Columbus Circle Investors, exiting entirely with an estimated $5.9M sold.

  • 62 institutional investors held OncoMed Pharmaceuticals, Inc. (OMED) as of Q3 2014, down from 63 in Q2 2014.
  • Funds reported $143M of OncoMed Pharmaceuticals, Inc. stock for Q3 2014, down 7.9% quarter-over-quarter.
  • 6 funds opened new OncoMed Pharmaceuticals, Inc. positions in Q3 2014 and 7 closed out, a net change of -1 holder.
  • The largest OncoMed Pharmaceuticals, Inc. buyer in Q3 2014 was BVF Inc, an estimated $9.29M added.
  • The largest OncoMed Pharmaceuticals, Inc. seller in Q3 2014 was Columbus Circle Investors, an estimated $5.9M sold.

Based on aggregated 13F filings for Q3 2014.